Measles Market: Global Industry Analysis and Forecast (2024-2030)

  • Measles Market size was valued at USD 1.70 Bn. in 2023 and the total Measles Market size is expected to grow at a CAGR of 7.20% from 2024 to 2030, reaching nearly USD 2.89 Bn. by 2030.

  • Format : PDF | Report ID : SMR_2138

Measles Market Overview

Measles is the most infectious diseases in human, this cause very serious illness, lifelong complications and death. Measles or rubeola is known to be a highly contagious disease. This disease is also caused by the virus of rubeola.

 

There are several drivers such as increasing immunization programs and government initiatives, outbreaks of measles in various regions, advancements in vaccine technology and rising awareness and education efforts helps to boost measles market growth. Restraints such as vaccine hesitancy and misinformation and logistical and supply chain challenges hampers the measles market growth. North America region is the dominating region thanks to rising patient population with measles and well-developed technology in the region. Europe region is expected to grow in the forecast period. Key Players such Astellas Pharma Inc., Emergent BioSolutions Inc., Abbott, Biomedical Diagnostics are major dominating companies across the world.

Measles Market

 

To get more Insights: Request Free Sample Report

 

Measles Market Dynamics

Increasing Immunization Programs and Government Initiatives and Outbreaks of Measles in Various Regions helps to Grow Measles Market.

The Globally increase in vaccination programs and government Initiatives for the significant growth of measles vaccine market. Various Countries have executed broad vaccination campaigns to control the spread measles. which is highly infectious and leads to prompt extreme unexpected problems.

 

The world health organization (WHO) and UNICEF conducting mass vaccination campaigns regularly in the regions with low vaccine coverage. Governments and international health organizations provides significant funding and logistical support, prompting a growing demand for measles vaccines. As these programs extend and heighten, the market for measles vaccines is expected to grow correspondingly. Regardless of the accessibility of vaccines, there have been different outbreaks of measles across globe.

 

Different factors such vaccine hesitancy, misinformation, and gaps in vaccination coverage contribute to these outbreaks. For instance, recently, there have been significant measles outbreaks in the Europe, US, and parts of Africa. Health authorities and governments respond to these outbreaks by increasing vaccine supplies and promoting immunization, which further fuels measles market growth.

 

Advancements in Vaccine Technology and Rising Awareness and Education Efforts Boost the Measles Market.

Advancements in Vaccine Technology is boosting the measles vaccine market growth. The advancement and developments of vaccine combination such as the MMR vaccine, which targets measles, mumps, and rubella, has made vaccination more efficient and appealing. This helps to improve overall compliance and reduced number of injections. Additionally, improvements in cold chain logistics and storage have facilitated better distribution, especially in remote and underserved areas. These technological strides have contributed to the increased global use and acceptance of measles vaccines.

 

Public awareness and education campaigns about the significance of vaccination have essentially affected the measles market. Health organizations, non-profits, and advocacy groups have effectively advanced the advantages of vaccination and addressing misconceptions about vaccine safety. Awareness in schools, public venues, and through media expect to guidance about risks regarding measles and the basic role of vaccines in preventing outbreaks. As awareness increases, it leads to higher vaccination rates as more individuals recognize the importance of immunization for personal and public health. This growing consciousness and informed public perspective bolster the demand for measles vaccines and support measles market growth.

 

Expansion of Immunization Programs in Emerging Markets

Many emerging Companies are focusing on their Vaccine program expansion to combat the diseases such as measles. World health Organizations and governments are investing in vaccination campaigns to reach more remote and underserved populations. This is the significant opportunity for vaccine manufacturer to stand out new market and increase their growth. By leveraging global health initiatives and collaborating with local health authorities, vaccine companies establish their strong presence in the market of that region. and contribute to reducing measles prevalence globally.

 

Development of Novel Vaccination Technologies

The ongoing advancements offers opportunities for innovation in in vaccine technology in the measles market. For more effective, require fewer doses, and have enhanced storage stability, research and development efforts are focused on develop vaccines. Such as development of needle-free delivery systems or vaccines not require refrigeration that revolutionize vaccine administration in resource-limited settings. Companies focuses on the technologies that gains a viable edge by offering safer, more convenient, and cost-effective measles vaccines that meet the evolving needs of healthcare systems globally.

 

Vaccine Hesitancy and Misinformation:

Vaccine hesitancy, powered by misinformation and distrust in vaccines, represents a significant challenge in the measles market. In spite of the demonstrated adequacy and safety of vaccines, including those for measles, a few people and networks hesitate or decline to receive an immunization shot. This hesitancy leads to suboptimal vaccination coverage rates, increasing the risk of measles outbreaks. Tending to immunization reluctance requires far reaching government funded training efforts, building trust in medical care suppliers, and countering misinformation spread through different media channels.

 

Logistical and Supply Chain Challenges:

The measles vaccine requires a virus chain for storage and transportation, which presents strategic difficulties, especially in regions with limited infrastructure. Keeping up with the vaccine's strength during storage and distribution is significant for its viability. Issues, for example, lacking storerooms, temperamental power supply for refrigeration, and difficulties in reaching remote areas impact vaccine availability and coverage. Further developing cold chain infrastructure, upgrading production network the management practices, and investing in alternative vaccine delivery methods helps mitigate these challenges in the measles market.

 

Measles Market Segment Analysis

Based on Type, In the measles market segment analysis by type, Red Measles (also known as Rubeola) is the dominating segment. Red Measles segment is dominating the market thanks to the higher incidence and severity of Red Measles compared to German Measles (Rubella). This leads to very serious health problems to children like pneumonia, encephalitis, and even death, particularly in young children, and it is very contagious. This required extensive vaccination efforts and heightened awareness campaigns to control and prevention.

 

Various national health agencies and the World Health Organization (WHO) prioritize Red Measles extermination through widespread vaccination programs, increasing the demand for the Red Measles vaccine. Consequently, this heightened focus on combating Red Measles contributes to its market dominance over German Measles. Consequently, this heightened focus on combating Red Measles contributes to its measles market dominance over German Measles.

Measles Market1

Based on Treatment, In the measles market, the Vaccine segment is clearly the leader among treatment options. This is largely causing vaccines are extremely effective at forestalling the disease, significantly cutting down the quantity of measles cases. Immunization is the essential methodology for controlling and eradicating measles globally. The MMR immunization, which safeguards against measles, mumps, and rubella, is especially powerful and generally utilized. General wellbeing drives and missions by associations like the World Health Organization (WHO) and UNICEF have focused on vaccination, bringing about broad vaccination endeavours around the world.

 

These endeavours have decisively decreased the rate of measles episodes. Unlike antiviral and antibiotic treatments, which are used to manage symptoms and secondary infections after someone has already contracted the disease, vaccines offer a proactive solution by preventing the disease in the first place. This proactive approach makes the Vaccine segment the most dominant in the measles treatment market.

Measles Market2

Measles Market Regional Analysis

North America Measles Market, North America is the dominating region of measles Market, and it is expected to continuous its dominance during the forecast period. The Dominance of north America region thanks to rising patient population with measles and well-developed technology in the region. In the United States, the quantity of instances of measles has reduced fundamentally on account of the immunization. In any case, the rising immunization refusals as of late are happening the measles in the US. addition, the regional market development relies upon the presence of a portion of the leading players, high healthcare expenditure and rising prevalence of immunological diseases in the region.

 

European measles market is expected to be the dominate market during the forecast period. This regional market is growing thanks to the availability of funds for research and developmental activities and the rising support of the government. Furthermore, the Asia pacific regional market for measles is predicted to be growing market across the global during the forecast period thanks to the rapidly developing healthcare sector and rising population base in the region. Moreover, the Middle East & African regional market is expected to produce the least market share during the forecast period thanks to the poor economic and political conditions and limited availability of medical facilities in the region.

Measles Market3

Measles Market Scope

Market Size in 2023

USD 1.70 Bn.

Market Size in 2030

USD 2.89 Bn.

CAGR (2024-2030)

7.20 %

Historic Data

2018-2022

Base Year

2023

Forecast Period

2024-2030

   Segments

By Type

  • German Measles
  • Red Measles

By Application

  • Adults
  • Children

By Treatment 

  • Antiviral Treatment
  • Antibiotic Treatment
  • Vaccine
  • Others

By End-Users

  • Clinics
  • Hospital
  • Others

Regional Scope

North America- United States, Canada, and Mexico

Europe – United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe

Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC

Middle East and Africa - South Africa, GCC, Egypt, Rest of the Middle East and Africa

South America – Brazil, Argentina, Rest of South America

 

Key Players Measles Market

  1. Astellas Pharma Inc.                   
  2. Emergent BioSolutions Inc.
  3. Abbott
  4. Biomedical Diagnostics
  5. Serum Institute of India Pvt. Ltd.
  6. Sanofi
  7. Novartis AG
  8. Johnson & Johnson Services, Inc.
  9. MedImmune
  10. CSL Limited
  11. GlaxoSmithKline plc
  12. Bavarian Nordic
  13. Merck & Co., Inc.
  14. Microgen
  15. Pfizer Inc.
  16. Bharat Biotech
  17. Sinovac Biotech
  18. Indian Immunologicals Limited
  19. Novavax
  20. Bio Farma
  21. Takeda Pharmaceutical Company Limited


Frequently Asked Questions

Increasing Immunization Programs and Government Initiatives, Outbreaks of Measles in Various Regions, Advancements in Vaccine Technology and Rising Awareness and Education Efforts are expected to be the major drivers of the market.

1.    Measles Market: Research Methodology 
2.    Measles Market: Executive Summary
3.    Measles Market: Competitive Landscape
4.    Potential Areas for Investment

4.1. Stellar Competition Matrix
4.2. Competitive Landscape
4.3. Key Players Benchmarking
4.4. Market Structure
4.4.1.    Market Leaders 
4.4.2.    Market Followers
4.4.3.    Emerging Players

4.5. Consolidation of the Market
5.    Measles Market: Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Challenges
5.5. Market Trends by Region
5.5.1.    North America
5.5.2.    Europe
5.5.3.    Asia Pacific
5.5.4.    Middle East and Africa
5.5.5.    South America

5.6. Market Drivers by Region
5.6.1.    North America
5.6.2.    Europe
5.6.3.    Asia Pacific
5.6.4.    Middle East and Africa
5.6.5.    South America

5.7. Market Restraints
5.8. Market Opportunities
5.9. Market Challenges
5.10. PORTER’s Five Forces Analysis
5.11. PESTLE Analysis
5.12. Strategies for New Entrants to Penetrate the Market
5.13. Analysis of Government Schemes and Initiatives for the Measles Industry
5.14. Regulatory Landscape by Region
5.14.1.    North America
5.14.2.    Europe
5.14.3.    Asia Pacific
5.14.4.    Middle East and Africa
5.14.5.    South America

6.    Measles Market Size and Forecast by Segments (by Value Units)
6.1. Measles Market Size and Forecast, by Type (2023-2030)
6.1.1.    German Measles
6.1.2.    Red Measles

6.2. Measles Market Size and Forecast, by Application (2023-2030)
6.2.1.    Adults
6.2.2.    Children

6.3. Measles Market Size and Forecast, by Treatment (2023-2030)
6.3.1.    Antiviral Treatment
6.3.2.    Antibiotic Treatment
6.3.3.    Vaccine
6.3.4.    Others

6.4. Measles Market Size and Forecast, by End-Users (2023-2030)
6.4.1.    Clinics
6.4.2.    Hospital
6.4.3.    Others

6.5. Measles Market Size and Forecast, by Region (2023-2030)
6.5.1.    North America
6.5.2.    Europe
6.5.3.    Asia Pacific
6.5.4.    Middle East and Africa
6.5.5.    South America

7.    North America Measles Market Size and Forecast (by Value Units)
7.1. North America Measles Market Size and Forecast, by Type (2023-2030)
7.1.1.    German Measles
7.1.2.    Red Measles

7.2. North America Measles Market Size and Forecast, by Application (2023-2030)
7.2.1.    Adults
7.2.2.    Children

7.3. North America Measles Market Size and Forecast, by Treatment (2023-2030)
7.3.1.    Antiviral Treatment
7.3.2.    Antibiotic Treatment
7.3.3.    Vaccine
7.3.4.    Others

7.4. North America Measles Market Size and Forecast, by End-Users (2023-2030)
7.4.1.    Clinics
7.4.2.    Hospital
7.4.3.    Others

7.5. North America Measles Market Size and Forecast, by Country (2023-2030)
7.5.1.    United States
7.5.2.    Canada
7.5.3.    Mexico

8.    Europe Measles Market Size and Forecast (by Value Units)
8.1. Europe Measles Market Size and Forecast, by Type (2023-2030)
8.1.1.    German Measles
8.1.2.    Red Measles

8.2. Europe Measles Market Size and Forecast, by Application (2023-2030)
8.2.1.    Adults
8.2.2.    Children

8.3. Europe Measles Market Size and Forecast, by Treatment (2023-2030)
8.3.1.    Antiviral Treatment
8.3.2.    Antibiotic Treatment
8.3.3.    Vaccine
8.3.4.    Others

8.4. Europe Measles Market Size and Forecast, by End-Users (2023-2030)
8.4.1.    Clinics
8.4.2.    Hospital
8.4.3.    Others

8.5. Europe Measles Market Size and Forecast, by Country (2023-2030)
8.5.1.    UK
8.5.2.    France
8.5.3.    Germany
8.5.4.    Italy
8.5.5.    Spain
8.5.6.    Sweden
8.5.7.    Russia
8.5.8.    Rest of Europe

9.    Asia Pacific Measles Market Size and Forecast (by Value Units)
9.1. Asia Pacific Measles Market Size and Forecast, by Type (2023-2030)
9.1.1.    German Measles
9.1.2.    Red Measles

9.2. Asia Pacific Measles Market Size and Forecast, by Application (2023-2030)
9.2.1.    Adults
9.2.2.    Children

9.3. Asia Pacific Measles Market Size and Forecast, by Treatment (2023-2030)
9.3.1.    Antiviral Treatment
9.3.2.    Antibiotic Treatment
9.3.3.    Vaccine
9.3.4.    Others

9.4. Asia Pacific Measles Market Size and Forecast, by End-Users (2023-2030)
9.4.1.    Clinics
9.4.2.    Hospital
9.4.3.    Others

9.5. Asia Pacific Measles Market Size and Forecast, by Country (2023-2030)
9.5.1.    China
9.5.2.    S Korea
9.5.3.    Japan
9.5.4.    India
9.5.5.    Australia
9.5.6.    ASEAN
9.5.7.    Rest of Asia Pacific

10.    Middle East and Africa Measles Market Size and Forecast (by Value Units)
10.1. Middle East and Africa Measles Market Size and Forecast, by Type (2023-2030)
10.1.1.    German Measles
10.1.2.    Red Measles

10.2. Middle East and Africa Measles Market Size and Forecast, by Application (2023-2030)
10.2.1.    Adults
10.2.2.    Children

10.3. Middle East and Africa Measles Market Size and Forecast, by Treatment (2023-2030)
10.3.1.    Antiviral Treatment
10.3.2.    Antibiotic Treatment
10.3.3.    Vaccine
10.3.4.    Others

10.4. Middle East and Africa Measles Market Size and Forecast, by End-Users (2023-2030)
10.4.1.    Clinics
10.4.2.    Hospital
10.4.3.    Others

10.5. Middle East and Africa Measles Market Size and Forecast, by Country (2023-2030)
10.5.1.    South Africa
10.5.2.    GCC
10.5.3.    Egypt
10.5.4.    Rest of ME&A

11.    South America Measles Market Size and Forecast (by Value Units)
11.1. South America Measles Market Size and Forecast, by Type (2023-2030)
11.1.1.    German Measles
11.1.2.    Red Measles

11.2. South America Measles Market Size and Forecast, by Application (2023-2030)
11.2.1.    Adults
11.2.2.    Children

11.3. South America Measles Market Size and Forecast, by Treatment (2023-2030)
11.3.1.    Antiviral Treatment
11.3.2.    Antibiotic Treatment
11.3.3.    Vaccine
11.3.4.    Others

11.4. South America Measles Market Size and Forecast, by End-Users (2023-2030)
11.4.1.    Clinics
11.4.2.    Hospital
11.4.3.    Others

11.5. South America Measles Market Size and Forecast, by Country (2023-2030)
11.5.1.    Brazil
11.5.2.    Argentina
11.5.3.    Rest of South America

12.    Company Profile: Key players
12.1. Astellas Pharma Inc. 
12.1.1.    Company Overview
12.1.2.    Financial Overview
12.1.3.    Business Portfolio
12.1.4.    SWOT Analysis
12.1.5.    Business Strategy 
12.1.6.    Recent Developments        

12.2. Emergent BioSolutions Inc. 
12.3. Abbott
12.4. Biomedical Diagnostics 
12.5. Serum Institute of India Pvt. Ltd. 
12.6. Sanofi
12.7. Novartis AG
12.8. Johnson & Johnson Services, Inc. 
12.9. MedImmune 
12.10. CSL Limited 
12.11. GlaxoSmithKline plc 
12.12. Bavarian Nordic 
12.13. Merck & Co., Inc.
12.14. Microgen
12.15. Pfizer Inc.
12.16. Bharat Biotech
12.17. Sinovac Biotech
12.18. Indian Immunologicals Limited
12.19. Novavax
12.20. Bio Farma
12.21. Takeda Pharmaceutical Company Limited
13.    Key Findings
14.    Industry Recommendation

Enquiry Before Buy


Request Sample PDF